Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in endocrinology, women’s health, immunology, and oncology. The ABCL news feed on Stock Titan aggregates company announcements, clinical updates, financial disclosures, and other material events drawn from AbCellera’s press releases and regulatory filings.
Investors and followers of ABCL can use this page to review news on AbCellera’s internal pipeline, including its lead programs ABCL635 and ABCL575. Recent announcements describe ABCL635 as a potential first-in-class non-hormonal antibody treatment for moderate-to-severe vasomotor symptoms associated with menopause, now in a Phase 1/2 clinical trial, and ABCL575 as an Fc-silenced, half-life extended investigational antibody therapy in a Phase 1 study for moderate-to-severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions.
The ABCL news stream also captures business and corporate developments, such as quarterly business results, updates on partner-initiated programs and molecules in the clinic, and changes in leadership and board composition. In addition, it includes disclosures on legal and intellectual property matters, including AbCellera’s settlement and patent license agreement with Bruker Corporation that resolved patent litigation globally and provides for upfront and royalty payments.
By reviewing this curated news page, readers can follow how AbCellera advances its antibody discovery and development engine, expands its clinical-stage pipeline, and manages its partnered programs and intellectual property. Bookmark this ABCL news section to quickly access company-issued updates, earnings announcements, clinical trial milestones, and other material information relevant to AbCellera’s operations and strategy.
AbCellera (Nasdaq: ABCL) announced that its antibody, bamlanivimab (LY-CoV555), demonstrated a significant reduction in COVID-19 risk among long-term care residents and staff in the Phase 3 BLAZE-2 trial. Data showed an up to 80% risk reduction in COVID-19 contraction for residents receiving bamlanivimab compared to placebo. Importantly, no COVID-19 related deaths were reported in the bamlanivimab group. The trial, in partnership with Lilly and NIAID, highlights the potential of bamlanivimab in preventing COVID-19, especially among vulnerable populations.
AbCellera (Nasdaq: ABCL) has expanded its intellectual property portfolio with the issuance of patent no. 10,881,084 for its Trianni Mouse® technology, aimed at enhancing antibody discovery. This technology allows the generation of fully human monoclonal antibodies, significantly increasing the speed and efficiency of therapeutic antibody development with partners. Carl Hansen, CEO, emphasized the patent's importance for protecting their proprietary technology in the U.S. The Trianni Mouse® platform is a key asset for developing advanced transgenic mouse technologies.
AbCellera (Nasdaq: ABCL) announced that bamlanivimab (LY-CoV555), developed with Eli Lilly, will undergo a new pragmatic study targeting high-risk COVID-19 patients. This collaboration, with support from New Mexico, aims to evaluate bamlanivimab's effectiveness and safety in diverse environments. The antibody, authorized in the U.S. and Canada, has demonstrated success in reducing viral load and hospitalizations in previous studies. This initiative aligns with AbCellera's efforts in pandemic response, showcasing its capabilities developed over two years under DARPA's program.
AbCellera Biologics (Nasdaq: ABCL) has successfully closed its initial public offering of 27,772,500 common shares at $20.00 each, raising approximately $555.5 million before expenses. This includes the full exercise of underwriters' options for 3,622,500 additional shares. Following the IPO, convertible promissory notes worth around $90.0 million converted into 6,093,524 common shares at $17.00 per share. Credit Suisse and several other banks served as joint book-running managers for this offering.
AbCellera Biologics has priced its initial public offering (IPO) at $20.00 per share, offering 24,150,000 common shares, expected to yield gross proceeds of $483 million. The IPO is set to trade on Nasdaq under the ticker 'ABCL' starting December 11, 2020, with an anticipated closing date of December 15, 2020. Should underwriters exercise their option, an additional 3,622,500 shares may be purchased. Concurrently, $90 million in convertible notes issued previously will convert at $17.00 per share, reflecting a discount to IPO price.